IP Library Granted Patent US 7,232,571
Granted Patent B2
US 7,232,571 · App. 10/978,726 · Granted Jun 19, 2007

Methods for reducing cholesterol using

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,232,571
App. No.
10/978,726
Granted
Jun 19, 2007
Kind
B2
Abstract

The invention describes therapeutic compositions including a lactic acid-producing bacteria, such as isolated Bacillus coagulans , in combination with a bifidogenic oligosaccharides or other cholesterol-reducing agents for use in reducing LDL cholesterol and serum triglycerides. Also described are therapeutic methods using the compositions and systems containing the therapeutic compositions.

Claims (27)

1. A method for decreasing serum cholesterol, decreasing serum triglycerides, and increasing serum HDL in a patient comprising administering to said patient an effective amount of a composition comprising viable Bacillus coagulans bacteria.

2. The method of claim 1 , wherein said Bacillus coagulans bacteria are Bacillus coagulans subspecies Hammer.

3. The method of claim 1 , wherein said Bacillus coagulans bacteria are Bacillus coagulans subspecies Hammer deposited under ATCC deposit number 31284.

4. The method of claim 1 , wherein said composition contains 2×10 5 to 1×10 10 viable bacteria per gram of composition.

5. The method of claim 1 , wherein said composition contains 1×10 7 to 1×10 10 viable bacteria per gram of composition.

6. The method of claim 1 , wherein said administering comprises introducing into the digestive tract from 10 8 to 10 10 viable bacteria per day.

7. The method of claim 1 , wherein said composition contains 5×10 8 to 1×10 9 viable bacteria per gram of composition.

8. The method of claim 1 wherein said administering comprises introducing into the digestive tract from 5×10 8 to 5×10 9 viable bacteria per day.

9. The method of claim 1 , wherein said administering comprises oral ingestion of said composition.

10. The method of claim 1 , wherein said administering comprises introducing into the digestive tract from 0.1 to 5 grams per day of said composition.

11. The method of claim 1 , wherein composition is in the form of a capsule, tablet, powder, semi-solid formulation, liquid, gel, suspension, or aerosol spray.

12. The method of claim 1 , wherein said composition further comprises a cholesterol-reducing agent.

13. The method of claim 1 , wherein said cholesterol-reducing agent is selected from the group consisting of a statin, a bile sequestering compound, a fiber product capable of binding cholesterol, niacin and aspirin.

14. The method of claim 13 , wherein said statin is selected from the group consisting of cerivastatin, fluvastatin, lovastatin, pravastatin and simvastatin.

15. The method of claim 14 , wherein said administering comprises introducing into the digestive tract from 10 to 80 milligrams of statin per day.

16. The method of claim 13 , wherein said bile sequestering compound is selected from the group consisting of colestipol and cholestyramine.

17. The method of claim 16 , wherein said administering comprises introducing into the digestive tract from 1 to 20 grams of bile sequestering compound per day.

18. The method of claim 16 , wherein said administering comprises introducing into the digestive tract from 6 to 8 grams of bile sequestering compound per day.

19. The method of claim 13 , wherein said fiber product is selected from the group consisting of gemfibrozil, fenofibrate, psyllium, bran, glucomannan and Jerusalem artichoke flour.

20. The method of claim 19 , wherein said administering comprises introducing into the digestive tract from 500 milligrams to 50 grams of fiber per day.

21. The method of claim 1 , wherein said composition further comprises a cholic acid complexation agent.

22. The method of claim 21 , wherein said complexation agent is a salt of a metal selected from the group consisting of calcium, chromium, copper, iodine, iron, magnesium, manganese, potassium sodium, and zinc.

23. The method of claim 22 , wherein said metal salt is provided in the form of calcium citrate, potassium gluconate, magnesium citrate or chromium picollinate.

24. The method of claim 1 , wherein said composition further comprises a food substance, flavoring, vitamin or mineral.

25. The method of claim 24 , wherein said vitamin is selected from the group consisting of choline, B-6, B-12, niacin, pantothenic acid, riboflavin, inositol, thiamine, and folic acid.

26. The method of claim 1 , wherein said patient is at risk for atherosclerosis, arterial sclerosis, myocardial infarction, heart attack, diabetes, coronary heart disease, angina pectoris or unstable angina.

27. A method for decreasing serum cholesterol, decreasing serum triglycerides, and increasing serum HDL in a patient comprising administering to the digestive tract of said patient an effective amount of a composition comprising viable Sporolactobacillus P44 bacteria.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Sep 12, 2017
From: SILICON VALLEY BANK
To: GANEDEN BIOTECH, INC.
Reel/Frame 043822/0897 →
SECURITY AGREEMENT Recorded Oct 10, 2012
From: GANEDEN BIOTECH, INC.
To: SILICON VALLEY BANK
Reel/Frame 029103/0069 →
LICENSE Recorded Jul 19, 2011
From: GANEDEN BIOTECH, INC.
To: SCHIFF NUTRITION GROUP, INC.
Reel/Frame 026616/0128 →
SECURITY AGREEMENT Recorded Jul 19, 2011
From: GANEDEN BIOTECH, INC.
To: SCHIFF NUTRITION GROUP, INC.
Reel/Frame 026616/0950 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2007
From: FARMER, SEAN; LEFKOWITZ, ANDREW R.
To: GANEDEN BIOTECH, INC.
Reel/Frame 019197/0680 →